Switzerland · Delayed Price · Currency is CHF Novartis AG Earnings Call Transcripts
Fiscal Year 2026
-
Priority brands and new launches drove strong Q1 growth, offsetting U.S. generic erosion and higher R&D spend. Full-year guidance is reaffirmed, with H2 expected to show stronger growth as generic impacts fade. Multiple pipeline readouts and new launches are set to support long-term growth.
-
The AGM celebrated a strong financial year with 8% sales growth, a 5.7% dividend increase, and robust pipeline progress. Shareholders approved all board proposals, raised concerns on executive pay and transparency, and discussed strategic investments and restructuring impacts.
-
Strong financial performance and robust free cash flow support a focused strategy on core therapeutic areas, technology platforms, and geographic priorities. A deep pipeline, active business development, and commercial execution underpin long-term growth targets, with significant upcoming product launches and continued commitment to ESG and innovation.
Fiscal Year 2025
-
Delivered 8% sales growth and 14% core operating income growth in 2025, achieving a 40.1% core margin two years ahead of plan. Key brands drove strong performance, with robust free cash flow and continued pipeline progress. 2026 guidance anticipates low single-digit sales growth amid major patent expiries.
-
Focused on innovative medicines, the company advances global health with new antimalarial therapies and Inclusive Health Accelerators to address disparities. Environmental and social impact targets are on track, with top ESG ratings and new commitments planned for 2026.
-
Novartis maintains a disciplined M&A strategy focused on high-value, innovative assets in core areas. Strong cash flow supports share buybacks and investments. AI-driven efficiencies should boost productivity. The company addresses evolving European pricing and U.S. policy changes. Cosentyx and Pluvicto remain key growth drivers, with guidance updates pending further data.
-
Sales and operating income growth remain strong, with upgraded mid-term guidance and a robust pipeline of late- and early-stage assets. Launch excellence, global expansion, and strategic M&A underpin growth, while ESG leadership and manufacturing expansion support long-term resilience.
-
Immunology remains a strategic focus, with RHAPSIDO launching as a first-in-class oral BTK inhibitor for CSU and ianalumab showing strong phase III results in Sjögren's disease. Both assets have significant expansion potential, supported by robust commercial infrastructure and ongoing late-stage pipeline development.
-
Q3 2025 saw 7% growth in both net sales and core operating income, driven by strong performances from priority brands like Kisqali, Pluvicto, and Scemblix, which offset generic erosion. The company reaffirmed its 2025 guidance and expects the Avidity acquisition to enhance long-term growth.
-
The acquisition expands the neuromuscular and RNA therapeutics portfolio, adding three late-stage assets with multibillion-dollar potential and leveraging commercial synergies. The $12 billion deal is expected to close in 2026, with long-term growth and margin recovery anticipated.
-
Double-digit sales and core margin growth in Q2 2025 led to upgraded full-year guidance. Priority brands like KISQALI, Kesimpta, PLUVICTO, and LEQVIO drove strong performance, while a new $10B share buyback and pipeline advances were announced.
-
Q1 2025 saw 15% sales growth and 27% core operating income growth, prompting upgraded full-year guidance. Key brands delivered strong double-digit growth, three new products were approved, and significant pipeline progress was made. Robust free cash flow enabled continued investment and shareholder returns.
-
The AGM highlighted strong financial growth, a dividend increase, and a strategic focus on innovative medicines and technology platforms. Shareholders approved all proposals, including new board appointments, while raising concerns about executive compensation and non-financial reporting.
-
The presentation highlighted a focused strategy on innovative medicines, robust financial performance, and a strong pipeline with key assets like KISQALI, Remibrutinib, and ianalumab driving growth into the 2030s. Operational scale, global market expansion, and leadership in technology platforms and ESG were emphasized.
Fiscal Year 2024
-
Q4 and full-year 2024 delivered record sales and income growth, with strong performance from key brands and robust pipeline momentum. 2025 guidance anticipates continued growth despite expected U.S. generic entries, with mid- to high-single-digit sales growth and margin expansion.
-
ESG and impact strategy is fully integrated with business goals, achieving top access and sustainability ratings. Progress includes rapid global medicine access, robust environmental targets, and resilient supply chains. ESG KPIs are tied to executive incentives, and digital innovation is driving efficiency and equity.
-
Upgraded guidance projects 6% sales CAGR through 2028 and 5% through 2029, with a focus on reaching 40%+ core margin by 2027. Commercial execution and R&D productivity have improved, supporting a specialty-focused, high-growth outlook. Share buybacks and disciplined capital allocation remain priorities.
-
Q3 2024 saw 10% sales and 20% core operating income growth, with strong performance across key brands and a third guidance raise for the year. New product launches and regulatory milestones drove momentum, while robust cash flow and margin expansion supported increased shareholder returns.
-
A comprehensive renal portfolio is being advanced, highlighted by Fabhalta's launch in IgA nephropathy and strong clinical data for atrasentan, zigakibart, and iptacopan. Commercial execution is robust, with rapid market access, targeted field deployment, and patient support. Peak sales guidance for iptacopan is $2-3 billion, with additional blockbusters expected.
-
Q2 2024 saw 11% sales growth and 19% core operating income growth, with strong performance across key brands and an upgraded full-year income outlook. Major pipeline advances, disciplined capital allocation, and ongoing innovation position the company for sustained growth despite regulatory and market headwinds.
-
Scemblix demonstrated superior efficacy and safety in the ASC4FIRST phase III trial for newly diagnosed CML, achieving faster and deeper molecular responses with fewer adverse events than current TKIs. Commercial strategy targets rapid adoption in the first-line setting, with projected peak global sales of $3 billion and strong support from physicians and payers.